eric topol glp 1 Dr. Topol: Pushing Medicine into the Future Eric Topol: GLP-1 Drugs Reduce

Introduction As the popularity of GLP-1 drugs for weight loss soared, the Food and Drug Administration (FDA) began announcing that FDA-approved versions of various GLP-1 drugs were going into shortage, starting with semaglutide (the active ingredient in Wegovy and Ozempic) in March 2022

Statements Author contributions AC and GLG contributed to conception of the review

The result is increased NAD+ levels, but through conservation rather than supplementation

Emr, The ESCRT pathway

Excess weight can negatively impact ones physical and emotional well-being and can lead to an increased risk of developing metabolic syndrome, cardiovascular health issues, insulin resistance, and type 2 diabetes

Factors like age, activity level, and thyroid function all influence metabolism